Comparative Pharmacology
Head-to-head clinical analysis: A POXIDE versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A POXIDE versus DORAL.
A-POXIDE vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (CrCl < 50 mL/min).
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine